Tags

Type your tag names separated by a space and hit enter

Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.
Ann Hematol. 2011 Oct; 90(10):1131-6.AH

Abstract

The clinical benefit of the addition of granulocyte colony-stimulating factor (G-CSF) to standard immunochemotherapy of chronic lymphocytic leukemia (CLL) with fludarabine, cyclophosphamide, and rituximab (FCR) is still unclear. In this retrospective study we analyzed the outcome of 32 consecutive patients with CLL during treatment with FCR. Sixteen patients received G-CSF for treatment of CTC grade 3 or 4 neutropenia or febrile neutropenia at some point during therapy and 16 did not. Both groups were well balanced for clinical and biological risk factors. Overall response rates were not significantly different (94% vs. 75%; p=0.144). Interestingly, a significantly better progression-free survival (100% vs. 35.4% at 24 months; p<0.001) and even overall survival (100% vs. 77.8% at 24 months; p=0.022) was observed in patients receiving G-CSF. While the underlying cause remains to be elucidated, these data strongly suggest an association of the addition of G-CSF to FCR therapy with final patient outcome.

Authors+Show Affiliations

Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, Austria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21617923

Citation

Gruber, Michaela, et al. "Prolonged Progression-free Survival in Patients With Chronic Lymphocytic Leukemia Receiving Granulocyte Colony-stimulating Factor During Treatment With Fludarabine, Cyclophosphamide, and Rituximab." Annals of Hematology, vol. 90, no. 10, 2011, pp. 1131-6.
Gruber M, Fleiss K, Porpaczy E, et al. Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab. Ann Hematol. 2011;90(10):1131-6.
Gruber, M., Fleiss, K., Porpaczy, E., Skrabs, C., Hauswirth, A. W., Gaiger, A., Vanura, K., Heintel, D., Shehata, M., Einberger, C., Thalhammer, R., Fonatsch, C., & Jäger, U. (2011). Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab. Annals of Hematology, 90(10), 1131-6. https://doi.org/10.1007/s00277-011-1260-x
Gruber M, et al. Prolonged Progression-free Survival in Patients With Chronic Lymphocytic Leukemia Receiving Granulocyte Colony-stimulating Factor During Treatment With Fludarabine, Cyclophosphamide, and Rituximab. Ann Hematol. 2011;90(10):1131-6. PubMed PMID: 21617923.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab. AU - Gruber,Michaela, AU - Fleiss,Karin, AU - Porpaczy,Edit, AU - Skrabs,Cathrin, AU - Hauswirth,Alexander W, AU - Gaiger,Alexander, AU - Vanura,Katrina, AU - Heintel,Daniel, AU - Shehata,Medhat, AU - Einberger,Christine, AU - Thalhammer,Renate, AU - Fonatsch,Christa, AU - Jäger,Ulrich, Y1 - 2011/05/27/ PY - 2010/11/30/received PY - 2011/05/16/accepted PY - 2011/5/28/entrez PY - 2011/5/28/pubmed PY - 2011/10/28/medline SP - 1131 EP - 6 JF - Annals of hematology JO - Ann. Hematol. VL - 90 IS - 10 N2 - The clinical benefit of the addition of granulocyte colony-stimulating factor (G-CSF) to standard immunochemotherapy of chronic lymphocytic leukemia (CLL) with fludarabine, cyclophosphamide, and rituximab (FCR) is still unclear. In this retrospective study we analyzed the outcome of 32 consecutive patients with CLL during treatment with FCR. Sixteen patients received G-CSF for treatment of CTC grade 3 or 4 neutropenia or febrile neutropenia at some point during therapy and 16 did not. Both groups were well balanced for clinical and biological risk factors. Overall response rates were not significantly different (94% vs. 75%; p=0.144). Interestingly, a significantly better progression-free survival (100% vs. 35.4% at 24 months; p<0.001) and even overall survival (100% vs. 77.8% at 24 months; p=0.022) was observed in patients receiving G-CSF. While the underlying cause remains to be elucidated, these data strongly suggest an association of the addition of G-CSF to FCR therapy with final patient outcome. SN - 1432-0584 UR - https://www.unboundmedicine.com/medline/citation/21617923/Prolonged_progression_free_survival_in_patients_with_chronic_lymphocytic_leukemia_receiving_granulocyte_colony_stimulating_factor_during_treatment_with_fludarabine_cyclophosphamide_and_rituximab_ L2 - https://dx.doi.org/10.1007/s00277-011-1260-x DB - PRIME DP - Unbound Medicine ER -